A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis
Latest Information Update: 18 Jan 2024
At a glance
- Drugs Abatacept (Primary) ; Branebrutinib (Primary)
- Indications Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 19 Oct 2023 This trial has been Spain in Germany, According to European Clinical Trials Database record.
- 01 Feb 2023 This trial has been completed in France (End Date: 5 Dec 2022) according to European Clinical Trials Database record.
- 25 Jan 2023 This trial has been Completed in Germany, According to European Clinical Trials Database record.